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ICEBERG: A Novel Inhibitor
of Interleukin-1b Generation
(Thornberry et al., 1992). The zymogen has low but de-
tectable enzymatic activity. Upon receipt of a proinflam-
matory signal, caspase-1 is thought to oligomerize and
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autoprocess to generate the active p10/p20 heterodi-*Department of Cellular and Molecular Biology
meric protease (Walker et al., 1994; Wilson et al., 1994;University of Michigan Medical School
Ghayur et al., 1997). The N-terminal prodomain appearsAnn Arbor, Michigan 48109
to play a critical role in this oligomerization-based acti-†Department of Molecular Oncology
vation of caspase-1 since its removal prevents pro-‡Department of Protein Engineering
cessing (Van Criekinge et al., 1996).Genentech, Inc.
At least one potential mechanism by which cas-South San Francisco, California 94080
pase-1 is regulated became evident with the identifica-
tion of a serine/threonine kinase RIP2/CARDIAK/RICK
(Inohara et al., 1998; McCarthy et al., 1998; Thome et al.,Summary
1998) that binds caspase-1 and promotes its processing
(Thome et al., 1998). RIP2 engages caspase-1 throughProIL-1b is a proinflammatory cytokine that is proteo-
a direct protein–protein interaction involving corre-lytically processed to its active form by caspase-1.
sponding caspase recruitment domains (CARDs) pres-Upon receipt of a proinflammatory stimulus, an
ent at the C terminus of RIP2 and within the prodomainupstream adaptor, RIP2, binds and oligomerizes
of caspase-1 (Hofmann et al., 1997; Thome et al., 1998).caspase-1 zymogen, promoting its autoactivation.
The CARD module mediates the interaction between aICEBERG is a novel protein that inhibits generation of
number of large prodomain caspases and their corre-IL-1b by interacting with caspase-1 and preventing its
sponding upstream activator adaptors, the prototypicalassociation with RIP2. ICEBERG is induced by proin-
examples being caspase-9 and Apaf-1 (Zou et al., 1997,flammatory stimuli, suggesting that it may be part of a
1999; Day et al., 1999; Qin et al., 1999). Structurally, thenegative feedback loop. Consistent with this, enforced
CARD motif resembles the death domain (DD) and theretroviral expression of ICEBERG inhibits lipopolysac-
death effector domain (DED). All possess six helices andcharide-induced IL-1b generation. The structure of
have a propensity to self associate. These homotypicICEBERG reveals it to be a member of the death-
interaction motifs form the molecular glue that bind thedomain-fold superfamily. The distribution of surface
signaling machinery responsible for caspase activationcharge is complementary to the homologous prodo-
(for a review, see Hofmann, 1999).main of caspase-1, suggesting that charge–charge in-
One powerful way to modulate assembly of such sig-teractions mediate binding of ICEBERG to the prodo-
naling complexes is through the presence of “decoy”main of caspase-1.
molecules that attenuate the assembly process. The
most dramatic examples of this are virally encodedIntroduction
DEDs from a number of g-herpesviruses including two
human oncogenic viruses (Kaposi sarcoma associated-Members of the caspase family of aspartate-specific
herpesvirus and molluscum contagiosum virus) thatcysteine proteases play a crucial role in both apoptosis
bind the DEDs of FADD and/or caspase-8 (FLICE) andand inflammation. The first mammalian member of this
disrupt assembly of the Fas-receptor associated deathfamily cloned, interleukin-1b converting enzyme (ICE),
inducing signaling complex (Hu et al., 1997; Thome et
now termed caspase-1 (for cysteinyl aspartate-specific
al., 1997). These viral proteins, termed v-FLIPs (for viral
protease), was originally discovered as the cytoplasmic
FLICE inhibitory proteins), function to effectively switch
protease responsible for the conversion of the 34 kDa off proapoptotic signaling from the Fas death receptor
inactive precursor IL-1b to the mature 17 kDa proinflam- (for reviews see Tschopp et al., 1998a, 1998b). The
matory cytokine (Cerretti et al., 1992; Thornberry et al., v-FLIPs are closely related to c-FLIP, an endogenous
1992; Miller et al. 1993). Caspase-1 has since been cellular protein present as various splice forms, the lon-
shown to process the cytokine precursor of IL-18 (inter- gest of which (c-FLIPL) is a potent inhibitor of FADD-
feron-g-inducing factor) (Ghayur et al., 1997; Gu et al., mediated caspase-8 activation (Hu et al., 1997; Irmler
1997). Underscoring the importance of this protease in et al., 1997). Therefore, both viral and cellular decoy
cytokine processing is the finding that caspase-1-defi- molecules are capable of regulating assembly of signal-
cient mice are remarkably resistant to LPS-induced en- ing complexes held together by homotypic interactions
dotoxic shock. Thus, caspase-1 is an attractive target for involving six-helix-bundle interaction domains. In a simi-
therapeutic intervention in inflammatory diseases (Kuida lar vein, we find that activation of caspase-1 and subse-
et al., 1995; Li et al., 1995). quent generation of IL-1b is regulated by a small CARD-
Caspase-1 is synthesized as a single-chain polypep- containing decoy molecule termed ICEBERG. This decoy
tide zymogen consisting of an N-terminal prodomain, protein binds the corresponding CARD motif present
and a large (p20) and a small (p10) catalytic domain in the prodomain of caspase-1, inhibiting and/or dis-
placing the upstream activator RIP2. ICEBERG works
through this mechanism to attenuate inflammation. The§ To whom correspondence should be addressed (e-mail: fairbro@
gene.com [W. J. F.], dixit@gene.com [V. M. D.] induction of ICEBERG by proinflammatory stimuli is con-
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Figure 1. Sequence and Expression of
ICEBERG
(A) Structural alignment of full length ICEBERG
with other CARD domains using the single
letter amino acid code. The locations of the
helices within ICEBERG are represented as
cylinders above the alignment. Helical re-
gions of other CARDs whose structures have
been solved are underlined. The charged
residues are colored (blue 5 basic, red 5
acidic). Starred residues are hydrophobic and
packed at the core of ICEBERG. Shading de-
notes residues identical to ICEBERG.
(B) Expression of ICEBERG. Human adult
cDNA panels were amplified with primers spe-
cific for either ICEBERG, RIP2, caspase-1, or
glyceraldehyde-3 phosphate dehydrogenase
(G3PDH). Tissues not shown include kidney,
lung, liver, and pancreas.
(C) Human adult tissue Northern blot probed
with ICEBERG cDNA.
sistent with it being a novel negative-feedback loop that (Figure 2A, left panels). In keeping with this notion, re-
moval of caspase-1 prodomain was found to abolishserves to eventually shut off IL-1b generation.
its binding to ICEBERG (Figure 2A, right panels). Using
bacterially expressed and purified ICEBERG and cas-Results
pase-1 prodomain, coimmunoprecipitation of the pro-
domain of caspase-1 is sufficient for direct ICEBERGIdentification of ICEBERG
interaction (Figure 2B). To ensure binding was not due toThe public EST database was searched for sequences
promiscuous CARD–CARD interactions, ICEBERG waswith significant homology to the CARD-containing pro-
incubated with other CARD-containing molecules; it diddomain of caspase-1 to identify regulators of caspase-1
not bind caspase-7, caspase-8, caspase-9, or RIP2 (Fig-activation. A novel 500 bp cDNA clone was identified
ure 2C and data not shown).that encoded an open reading frame with a predicted
molecular mass of 10.1 kDa. This protein, termed
ICEBERG, is 52% identical to the caspase-1 CARD (Fig- RIP2 Activates Caspase-1
ure 1A). Analysis of multiple tissue cDNA panels and The concept that oligomerization promotes autopro-
northern blots revealed that ICEBERG is primarily ex- cessing was originally proposed in studies where over-
pressed in the heart and placenta (Figures 1B and 1C). expressed zymogen was found to process itself to active
The related CARD-containing molecules caspase-1 and protease (Gu et al., 1995). Further studies suggested
RIP2 are also expressed in the heart and placenta as that zymogen self-association occurs through the pro-
well as in numerous other tissues (Figure 1B). domain (Van Criekinge et al., 1996). Consistent with this
idea, replacing the prodomain with an artificial oligo-
merizer will promote activation (MacCorkle et al., 1998;ICEBERG Binds Caspase-1
Based on sequence homology and the homotypic nature Muzio et al., 1998a; Srinivasula et al., 1998; Yang et al.,
1998). Activation of many large prodomain regulatoryof six-helix-bundle, death-domain-fold superfamily mem-
bers, we reasoned that ICEBERG would likely bind cas- caspases, including caspase-9, CED-3, and caspase-8,
results from induced proximity mediated by associationpase-1 through the cognate CARD-containing segments
ICEBERG: A Novel Inhibitor of IL-1b Generation
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Figure 2. Characterization of ICEBERG/Cas-
pase-1 Binding
(A) Interaction of ICEBERG with full length
caspase-1 (left panels). Removal of the cas-
pase-1 prodomain results in loss of ICEBERG
binding (right panels). Abbreviations for con-
structs include caspase-1 catalytic cysteine
to alanine mutant (abbreviated mt) and cas-
pase-1 with no prodomain (Dpro).
(B) Interaction of purified ICEBERG and puri-
fied prodomain of caspase-1. ICEBERG im-
munoprecipitates with caspase-1 (left panel,
lane 1) and caspase-1 immunoprecipitates
with ICEBERG (right panel, lane 6). Mono-
clonal gD antibody was used for the control
immunoprecipitation (lanes 2 and 7). Lanes
3, 4, 8, and 9 are negative controls. Lanes 5
and 10 are positive controls.
(C) ICEBERG does not interact with RIP2 or
other CARD-containing molecules including
caspase-9 and caspase-7. 293T cells were
transfected with the indicated plasmids and
immunoblotted as in (A).
with their respective upstream adaptor molecules APAF-1, RIP2-CARD bound purified caspase-1 prodomain, con-
firming that the purified CARDs could directly bind (Fig-CED-4, and FADD. The adaptor molecules function to
concentrate caspase zymogens so that neighboring ure 4D, lane 2). The self-association of the zymogen form
of caspase-1 upon overexpression was demonstratedmolecules accurately process each other at internal Asp
residues to generate the two-chain active enzyme (for using differentially epitope-tagged forms of the mole-
cule (Figure 3B, lane 1). However, in the presence ofa review, see Salvesen and Dixit, 1999).
RIP2/CARDIAK has been shown to bind and activate RIP2, caspase-1 self-association was enhanced and au-
toactivation evident as judged by generation of pro-caspase-1 (Thome et al., 1998). The ability of RIP2 and
caspase-1 to physically interact was further character- cessed subunits (Figure 3B, lane 2; Figure 3C). This was
further demonstrated using purified components (Figureized to investigate if RIP2 mediated oligomerization of
caspase-1 promoted its activation. 293T cells were tran- 4E, lane 3). Therefore, RIP2 enhances the activation of
caspase-1 by promoting its oligomerization in accordsiently cotransfected with RIP2 myc-his and caspase-1
gD followed by immunoprecipitation with either RIP2 or with the induced proximity model.
gD antibody. RIP2 bound caspase-1 quantitatively; the
converse was also true (Figure 3A). To determine if the ICEBERG Inhibits the Ability of RIP2
to Oligomerize Caspase-1interaction was through the CARD motif, RIP2-CARD
was expressed as a fusion to glutathione-S-transferase Given that oligomerization of caspase-1 initiates its acti-
vation, this step is likely to be highly regulated. To deter-(GST) and immobilized onto glutathione-Sepharose. The
Cell
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Figure 3. RIP2 Oligomerization and Activa-
tion of Caspase-1
(A) RIP2 binds caspase-1 (left and right upper
panels). Lower four panels show expression
of RIP2 and caspase-1 in the lysate used for
immunoprecipitation.
(B) RIP2 oligomerizes caspase-1. Differen-
tially tagged versions of caspase-1 were co-
transfected in the presence (right lane) or ab-
sence (left lane) of RIP2, immunoprecipitated
with FLAG-M2 beads (Sigma) and probed
with gD antibody to look for self-association
between differentially tagged caspase-1 pro-
teins. The blot was reprobed with aFLAG to
normalize for caspase-1 expression.
(C) RIP2 activates caspase-1. Caspase-1 was
expressed in the presence (right lane) or ab-
sence of RIP2 (left lane). Lysate was immuno-
precipitated with aFLAG and Western blotted
with aFLAG.
mine if ICEBERG inhibits the ability of RIP2 to oligo- could inhibit IL-1b generation, it was expressed in these
cells under the control of a retroviral promoter. The gen-merize caspase-1, 293T cells were transiently trans-
eration of IL-1b upon LPS stimulation was significantlyfected with RIP2 V5, caspase-1 gD, and caspase-1 FLAG
blunted in ICEBERG-expressing cells, consistent withwith or without ICEBERG HA. As noted previously, over-
the biochemical studies (Figure 5).expressed caspase-1 oligomerized and this was en-
While the exact details of how caspase-1 is activatedhanced by RIP2 expression (Figures 3B and 4A, lane 1
following LPS stimulation remain unclear, what is appar-versus lane 3). However, in the presence of ICEBERG,
ent is that cytokine generation and inflammation mustRIP2-mediated enhancement of oligomerization was in-
eventually be turned off. We hypothesized that ICEBERGhibited (Figure 4A, lane 5 versus lane 7). Consistent with
may fulfill such a role by acting as a physiologic inhibitorthis result, caspase-1 was no longer complexed to RIP2
of IL-1b generation. The production of IL-1b by immunebut now bound ICEBERG (Figure 4B, right panels). The
cells upon an inflammatory stimulus is a rapid posttrans-ability of ICEBERG to act as a potential regulator of cas-
lational event, with active cytokine generated in minutes.pase-1 activation was reaffirmed by showing ICEBERG
It would make teleological sense for inhibitors of theinhibits RIP2 mediated processing of caspase-1 (Figure
system to be dependent upon relatively slow new gene4C). Using purified recombinant proteins, we assessed
transcription/translation so that in the hours it takes toif the binding and inhibition by ICEBERG was direct.
generate them, the beneficial effects of inflammationRIP2-CARD expressed as a GST-fusion was immobi-
have begun to take place. Given this, we asked iflized onto glutathione beads and incubated with soluble
ICEBERG transcript was inducible by proinflammatorycaspase-1; ICEBERG was then added at an equimolar
agents such as LPS or TNF. Using exon-specific primersratio for defined time periods. The RIP2/caspase-1 com-
and RT-PCR, ICEBERG transcript was found to be LPS-plex was disrupted by the added ICEBERG as ICEBERG
and TNF-inducible (Figure 6A). This is a general phenom-preferentially bound caspase-1, leading to the release
enon confined not only to THP.1 cells, but also observedof caspase-1 from the RIP2 beads (Figure 4D, upper
with primary monocytes and endothelial cells (Figurepanel). This was confirmed by immunoprecipitating dis-
6A, lower six panels). Additionally, metabolic labelingplaced caspase-1 from the soluble fraction and finding
and immunoprecipitation revealed ICEBERG proteinit in complex with ICEBERG (Figure 4D, lower panel).
was also induced by LPS, being detectable 7 hr post-The possibility that ICEBERG was disrupting the RIP2/
stimulation (Figure 6B, lower panels). This induction ofcaspase-1 complex by binding RIP2 was discounted
ICEBERG coincided with reduction in caspase-1 activitybecause ICEBERG did not bind RIP2-CARD GST (data
(Figure 6B, lower graphs) and corresponding reductionnot shown) or full length RIP2 (Figure 2C). The ability
in IL-1b release (Figure 6B, upper graphs). Therefore,of RIP2 to activate purified caspase-1 was inhibited after exposure to LPS, there occurs an initial rapid burst
by purified ICEBERG (Figure 4E, lane 4). Therefore, of caspase-1 activation and IL-1b release, both of which
ICEBERG, by preferentially binding caspase-1, inhibits are rapidly attenuated coincident with the appearance
RIP2-mediated oligomerization of caspase-1 and, pre- of ICEBERG protein. This is in keeping with the proposed
sumably, the subsequent generation of downstream ac- negative feedback role of ICEBERG in regulating IL-1b
tive caspase-1 and IL-1b. production.
ICEBERG Is Upregulated by LPS and TNF and Endogenous Modulation of Caspase-1
Inhibits IL-1b Release from Monocytes in Response to LPS
THP.1 monocytes release IL-1b in response to an inflam- We generated monoclonal antibodies specific for RIP2
and caspase-1 to investigate the interactions observedmatory stimulus such as LPS. To test whether ICEBERG
ICEBERG: A Novel Inhibitor of IL-1b Generation
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Figure 4. ICEBERG Inhibits RIP2 Oligomerization and Activation of Caspase-1
(A) Caspase-1 oligomerization enhanced in the presence of RIP2 (lane 3 versus lane 1) is inhibited in the presence of ICEBERG (lane 7 versus
5). Negative control HA antibody is shown in lanes 2, 4, 6, and 8. Stable cells with or without ICEBERG were transfected with plasmids
expressing differentially tagged caspase-1 (as in Figure 3B). The coprecipitating caspase-1 was detected using a biotinylated aFLAG antibody
(Sigma) and visualized with streptavidin-peroxidase (Sigma; upper panel).
(B) RIP2 does not bind caspase-1 in the presence of ICEBERG as caspase-1 is bound to ICEBERG (upper right panels, right lane). RIP2 binds
caspase-1 in the absence of ICEBERG (upper left panel, right lane).
(C) The ability of RIP2 to activate caspase-1 is inhibited by ICEBERG. Stable cells with or without ICEBERG were cotransfected with RIP2
and caspase-1-gD. The clarified lysate was Western blotted with a gD antibody. RIP2 protein in the lysate is shown in the lower two panels.
(D) Purified ICEBERG displaces caspase-1 from RIP2. Caspase-1 prodomain was incubated with glutathione beads containing either RIP2-
CARD-GST or GST alone. After incubation, ICEBERG was added at an equimolar ratio to caspase-1. Washed beads were blotted for the
presence of caspase-1 prodomain (upper panel). The washes were precipitated for caspase-1 prodomain and Western blotted for the presence
of ICEBERG (lower panel).
(E) ICEBERG inhibits the ability of RIP2 to activate caspase-1 in a purified system. In vitro translated caspase-1 was incubated in activation
buffer containing either RIP2-CARD-GST or GST bound to glutathione beads in the presence or absence of ICEBERG.
with transfected molecules at the endogenous level. By (to induce ICEBERG), followed by immunoprecipitation
analysis. As shown (Figure 7C), caspase-1 antibodyimmunoprecipitation and subsequent immunoblotting,
we found that RIP2, as expected, associated with cas- (lane 3) but not control antibody (lane 2) coprecipitated
ICEBERG.pase-1 in an LPS dependent manner (Figure 7A). The
converse was also true (Figure 7B). The likely transient
nature of the activation complex between endogenous ICEBERG Solution Structure
Since modulators of caspase-1 activation represent at-RIP2 and caspase-1 is reflected in the fact that upon
LPS activation, only a small fraction of total caspase-1 tractive therapeutic targets, we determined the structure
of ICEBERG as a first step toward understanding theis found associated with RIP2 (compare lane 1 and 4,
Figure 7B). Indeed, this transient association made de- molecular basis of its interaction with caspase-1. The
solution structure of ICEBERG was determined usingtection problematic, requiring the use of large numbers
of cells and metabolic labeling to high specific activity. data from 3D heteronuclear NMR spectra obtained using
uniformly 15N-labeled and 15N/13C-labeled protein sam-Under these conditions, a weak association was ob-
served between endogenous RIP2 and caspase-1 that ples at pH 3.8 (at pH values $ 4.3, ICEBERG forms a
gel at concentrations required for NMR structure deter-was significantly enhanced upon LPS activation (com-
pare lanes 3 and 4, Figure 7B). To detect endogenous mination). The final structure is based on a total of 1238
experimentally derived internuclear distance and dihe-ICEBERG complexed to caspase-1, metabolically la-
beled THP.1 cells were pretreated for 12 hr with LPS dral angle restraints. The structure of ICEBERG is well
Cell
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core of the domains (Figure 1A). There are several differ-
ences, however, in the packing of the cores, as well as
in the loops between the helices and the lengths of the
helices; in particular, helices H1 and H6 are significantly
shorter in ICEBERG than in the other CARD structures.
The surface of ICEBERG contains three highly charged
patches (Figure 9A). Five basic residues from helix H1
(Arg7, Lys8, Lys9, Arg10, and Arg11), together with
Arg55 from H4 and Lys86 from H6, form a positively
charged patch on one surface. The opposite surface
is predominantly negatively charged with acidic side
chains contributed from the C-terminal ends of helices
H2 (Asp27, Glu31, and Asp32) and H5 (Glu78 and Glu79);
residues Glu33 and Asp80 might also be considered as
part of this patch. A second negatively charged surface
is found on the bottom of the structure, as presented
in Figure 9A, comprising acidic residues from the H4–H5
turn (Asp45, Glu46, and Asp48) and Asp52 from H5.
A homology model of the prodomain of caspase-1
revealed a distribution of surface charge similar to
ICEBERG, with a positively charged patch formed by
residues from helices H1 and H4, and a negatively
charged patch on the opposite surface formed by resi-
dues from helices H2 and H5 (Figure 9B). Similar to the
RAIDD/caspase-2 and Apaf-1/caspase-9 interactions
(Chou et al., 1998; Day et al., 1999; Qin et al., 1999;
Vaughn et al., 1999; Zhou et al., 1999), we propose that
charge–charge interactions are important for mediating
the interaction between ICEBERG and caspase-1. Con-
sistent with this suggestion, we observed no interaction
between ICEBERG and the caspase-1 prodomain at pH
3.8, where the acidic patches on both proteins are likelyFigure 5. ICEBERG Inhibits LPS Inducible IL-1b Production
protonated (data not shown).ICEBERG was expressed in THP.1 cells following infection with an
engineered retrovirus (Hawley et al., 1996). After LPS stimulation for The general similarity between the surface properties
6 hr, total IL-1b release from clonal cells was quantitated using an IL- of ICEBERG and the caspase-1 prodomain raised ques-
1b ELISA. Graph shows representative data from four independent tions regarding the binding specificity of RIP2 CARD,
experiments. ICEBERG expression is shown relative to tubulin (lower which binds to caspase-1 prodomain but not to
panels).
ICEBERG (Figure 2C and data not shown). To gain some
insight into these interactions we also built a homology
model of RIP2 CARD (Figure 9C). RIP2 CARD has adefined by the data (Table 1); the covalent geometry is
dramatically different surface charge distribution rela-also good with 84% of the `,c angles within the most
tive to ICEBERG and caspase-1 prodomain. The posi-favored regions of a Ramachandran plot for residues
tively charged patch centered around helix H1 in both5–89. The protein forms an antiparallel six-helix bundle
ICEBERG and caspase-1 prodomain has been neutral-with Greek-key topology and a well-defined hydropho-
ized in RIP2 CARD, and, in addition, this face has abic core (Figure 8). Helices H1–H5 are a-helical while
concave, negatively charged patch comprising residuesH6 is a 310 helix; H1 is interrupted by a distinct kink at
from helix H3, the C-terminal region of H4, and theresidue Lys9. As expected based on sequence compari-
N-terminal region of H5. Furthermore, the opposite sur-sons (Figure 1A), the global fold of ICEBERG places it
face of RIP2 CARD does not possess a negativelyin the death-domain structural superfamily that includes
charged patch as observed for ICEBERG and caspase-1DDs (Huang et al., 1996; Liepinsh et al., 1997; Jeong et
prodomain.al., 1999), DEDs (Eberstadt et al., 1998), and CARDs
(Chou et al., 1998; Day et al., 1999; Qin et al., 1999;
Vaughn et al., 1999; Zhou et al., 1999). Discussion
The structure of ICEBERG is most similar to those
determined recently for the CARDs of RAIDD (Chou et ICEBERG was identified as a novel protein bearing high
homology to the CARD of caspase-1. In vitro and in vivoal., 1998), Apaf-1 (Qin et al., 1999; Vaughn et al., 1999;
Zhou et al., 1999), and the prodomain of caspase-9 (Qin binding data showed that ICEBERG specifically associ-
ates with the prodomain of caspase-1 and that this inter-et al., 1999). The best-fit superpositions of Ca atoms
yielded RMSDs of 1.6 A˚ for 77 pairs of residues, 1.9 A˚ action inhibits binding of the upstream activator RIP2
to caspase-1. RIP2 has been shown previously to bindfor 81 pairs of residues, and 2.0 A˚ for 76 pairs of residues
for Apaf-1, caspase-9, and RAIDD CARDs, respectively. and activate caspase-1 (Thome et al., 1998). Our studies
confirm and extend these observations by suggesting thatStructural alignment of the four CARDs reveals a number
of conserved hydrophobic residues that make up the RIP2 acts as a nidus for oligomerization of caspase-1
ICEBERG: A Novel Inhibitor of IL-1b Generation
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Figure 6. Lipopolysaccharide and Tumor Necrosis Factor Upregulate ICEBERG Expression
(A) Transcription of ICEBERG mRNA increases following LPS or TNF treatment. The amount of RNA was normalized using glyceraldehyde-
3-phosphate specific primers (lower panel).
(B) ICEBERG protein is LPS inducible coincident with a decrease in IL-1b release and caspase-1 activity. THP.1 cells and primary monocytes
were treated with LPS and supernatants assayed for IL-1b (upper bar graphs). Lysates prepared from LPS-treated THP.1 cells and primary
monocytes were measured for their caspase-1 activity (middle bar graphs). To visualize ICEBERG, THP.1 cells and primary monocytes were
treated with LPS, metabolically labeled, and immunoprecipitated (lower panels).
zymogen, thereby promoting its proteolytic autoactiva- and 7B). In contrast, ICEBERG is induced through new
gene transcription and translation, a process that takestion, keeping with the induced proximity model (Figures
3B and 3C). The association of RIP2 with caspase-1 is several hours (Figures 6A and 6B). Once present, how-
ever, it functions to inhibit the association of RIP2 witha rapid and transient posttranslational event captured
only with difficulty at the endogenous level (Figures 7A caspase-1 (Figure 4B) and will, in fact, even dissociate
Figure 7. Endogenous Binding
(A) RIP2 binds caspase-1 in an LPS-depen-
dent manner (upper panel, lane 3 versus lane
1). THP.1 cells were immunoprecipitated for
caspase-1 and probed for RIP2. The amount
of caspase-1 and RIP2 immunoprecipitated
is shown in the lower panels.
(B) Caspase-1 binds RIP2 in an LPS-depen-
dent manner (upper panel, lane 3 versus lane
4). Same as in Figure 7A; however, the THP.1
cells were metabolically labeled and immuno-
precipitated for RIP2 followed by caspase-1.
(C) ICEBERG associates with caspase-1 in an
LPS-dependent manner (upper panel, lane 3).
Metabolically labeled THP.1 cells were im-
munoprecipited for caspase-1 followed by
ICEBERG.
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how much of the cytokine is produced. At low concen-Table 1. Summary of Structural Statistics for the 20 Final
trations, it functions primarily to mediate local inflamma-Structures of ICEBERG
tion, for example by causing mononuclear phagocytes
RMS deviation from experimental distance restraints (A˚)
and endothelial cells to synthesize chemokines that re-NOE
cruit and activate various leukocyte populations. How-All (1050) 0.0084 6 0.0006
Intraresidue (299) 0.0037 6 0.0009 ever, if synthesized in larger quantities, it can exert po-
Sequential (264) 0.0115 6 0.0017 tentially lethal systemic effects including fever, chills
Medium (249) 0.0090 6 0.0011 and shock (for reviews see Dinarello, 1997; O’Reilly et
Long (ji 2 jj . 4) (238) 0.0082 6 0.0012 al., 1999). Therefore, it is important to keep IL-1b levels
H-bonds (88) 0.0118 6 0.0016
in check to prevent a fatal outcome on exposure to aRMS deviation from experimental dihedral restraints (8)
minor proinflammatory insult. Reinforcing this notion is` (84), x1 (16) 0.098 6 0.050
NOE distance restraint violations the fact that IL-1 is the only cytokine to date for which
No. violations . 0.1 A˚ 0.15 6 0.37 naturally occurring inhibitors have been described. IL-1
Maximum violation (A˚) 0.09 6 0.01 receptor antagonist (IL-1ra) is structurally related to IL-1
Dihedral angle restraint violations and binds IL-1 receptors but is biologically inactive,
No. violations . 18 0.45 6 0.51
therefore functioning as a competitive inhibitor of IL-1Maximum violation (8) 0.96 6 0.49
(Carter et al., 1990). Our work suggests that ICEBERG,RMS deviations from idealized covalent geometry
Bonds (A˚) (1439) 0.0030 6 0.0002 like IL-1ra, functions to keep IL-1b levels in check but
Angles (8) (2622) 0.372 6 0.009 does so by an intracellular desensitization mechanism.
Planes (8) (696) 0.171 6 0.006 The essence of this involves the relatively slow protein
Energies (kcal·mol21) synthesis–dependent accumulation of ICEBERG that
ENOEa 4.37 6 0.62 negatively feeds back to inhibit binding of RIP2 to cas-ECDIH 0.07 6 0.07
pase-1 and also disrupts preformed RIP2/caspase-1Ebond 12.9 6 1.8
Eangle 55.4 6 2.7 complexes. Hence, the temporal difference between the
Eplane 3.1 6 0.2 rapid, posttranslational RIP2 (or equivalent) mediated
EvdWb 10.6 6 1.3 activation of caspase-1 and slow protein synthesis–
Etotal 86.5 6 5.6 dependent accumulation of the feedback inhibitor
a The final value of the square-well NOE (ENOE) and torsion angle ICEBERG provides a window of opportunity for con-
(ECDIH) potentials are calculated with force constants of 50 kcal· trolled generation of IL-1b so that its beneficial local
mol21·A˚22 and 200 kcal·mol21·rad22, respectively. proinflammatory effects predominate over potentially
b The quadratic van der Waals repulsion term (EvdW) is calculated deleterious systemic effects. In a related manner, thewith a force constant of 4 kcal·mol21·A˚24 with the van der Waals radii
induction of negative feedback inhibitors of inflamma-set to 0.8 times the values in the XPLOR parameter set PARMALLH6
tion such as ICEBERG may be the molecular mechanism(Linge and Nilges, 1999).
that underlies the phenomenon of tolerance where, fol-
lowing multiple inflammatory stimuli, the cellular re-
sponse is diminished (for reviews see Yoza et al., 1998;preformed complexes of RIP2 and caspase-1 (Figure
Zeisberger and Roth, 1998).4D). The net effect of its presence is to attenuate cas-
Components of the signaling pathway that mediatepase-1 activation (Figures 4C and 4E and Figure 6B,
activation of RIP2 upon engagement of proinflammatorylower graph) and IL-1b generation (Figure 6B, upper
receptors such as the toll-like (TL) receptors remain un-graph), a conclusion underscored by the finding that
clear. Two adaptor molecules likely involved are MyD88enforced retroviral expression of ICEBERG in THP.1
and TRAF6. Both have been shown to lie downstreamcells inhibits IL-1b generation in response to LPS (Fig-
of toll receptors and the IL-1 receptor (Medzhitov et al.,ure 5).
The biological effects of IL-1b depend on where and 1998; Muzio et al., 1998b; Yang et al., 1999). Further-
Figure 8. ICEBERG Structure
(A) Stereoview showing best fit superpositions (optimized for residues 5–89) of the backbone atoms (N, Ca, and C9) from the 20 NMR-derived
structures of ICEBERG. The side chain heavy atoms of hydrophobic residues are shown in red. The RMSD with respect to the mean coordinates
for this superposition is 0.25 6 0.04 A˚ for the backbone atoms and 0.71 6 0.05 A˚ for the heavy atoms.
(B) Schematic representation of the ICEBERG structure showing the packing of the six helices formed by residues 5–8 (H1a), 10–14 (H1b),
19–32 (H2), 37–44 (H3), 50–63 H4), 67–79 (H5), and 83–87 (H6). This figure was produced using the program MOLMOL (Koradi et al., 1996).
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Figure 9. Surface Potentials of ICEBERG,
Caspase-1, and RIP2
(A) The solvent-accessible molecular surface
of the minimized mean structure of ICEBERG
color coded according to electrostatic sur-
face potential: red, 28 kT; white, 0 kT; and
blue, 18 kT. The two views are related by a
1808 rotation about the vertical axis.
(B) The electrostatic surface potential of the
caspase-1 prodomain homology model.
(C) Electrostatic surface potential of the RIP2
CARD homology model. This figure was pro-
duced using the program GRASP (Nicholls,
1992).
more, mice homozygous null for MyD88 and TRAF6 are The CARDs of both RAIDD and Apaf-1 also have two
highly polar surfaces on opposite sides of the domains,resistant to LPS challenge (Kawai et al., 1999; Lomaga
et al., 1999). Significantly, TRAF6 has been shown to although the positions and sizes of these patches differ
from those observed for ICEBERG, as well as from eachbind RIP2 (McCarthy et al., 1998) so that a possible
scenario is for signaling information to flow from the other (Chou et al., 1998; Day et al., 1999; Qin et al., 1999;
Vaughn et al., 1999; Zhou et al., 1999) (Figure 1A). Thereceptor to MyD88 to TRAF6 and eventually to RIP2. This
is conjecture at the moment and awaits experimental caspase-2 and -9 prodomains also have distributions
of surface charge similar to their respective binding part-verification. RIP2 may be only one of many possible
activators of caspase-1 and its precise contribution to ners, RAIDD and Apaf-1 (Chou et al., 1998; Qin et al.,
1999; Vaughn et al., 1999; Zhou et al., 1999). The acidicthis pathway will only be accurately gauged once RIP2
knockout mice are available. residues on H2 and H3 of Apaf-1 CARD have been shown
to interact directly with basic residues on helices H1Understanding the molecular basis of the interactions
between the CARDs of ICEBERG, RIP2, and caspase-1 is and H4 of the caspase-9 prodomain (Qin et al., 1999;
Zhou et al., 1999). Charge–charge interactions have alsocentral to understanding their role in modulating cas-
pase-1 activation. To this end, we have determined the been proposed to mediate the homophilic CARD/CARD
interaction between RAIDD and caspase-2 (Chou et al.,solution structure of ICEBERG and constructed homol-
ogy models of the CARDs of caspase-1 and RIP2. The 1998). As for the RAIDD/caspase-2 and Apaf-1/cas-
pase-9 interactions, we propose that charge–charge in-surface properties of ICEBERG and the caspase-1 pro-
domain are in general similar, with each having distinct teractions are important for mediating the ICEBERG/
caspase-1 interaction. An important question is whetherpositively and negatively charged surfaces (Figure 9).
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solubilized with guanidine thiocyanate followed by cesium chloridean acidic patch on ICEBERG interacts with the basic
gradient centrifugation. RT-PCR was performed according to in-patch on caspase-1 or vice versa.
structions with the Perkin-Elmer RNA PCR kit using the oligo d(T)Given that RIP2 CARD contains a prominent acidic
primer. Levels of RNA were normalized using human glyceraldehyde
patch, but no such basic patch, one might speculate 3-phosphate dehydrogenase specific control primers (Clontech).
that the convex, positively charged patch on caspase-1
prodomain (Figure 9B) binds the concave, negatively
Northern Blot Analysis and cDNA Panel Analysis
charged patch of RIP2 (Figure 9C). If this were true, and Adult human multiple tissue Northern blots (Clontech) were hybrid-
given that ICEBERG competes with RIP2 for caspase-1 ized according to manufacturer’s instructions using radiolabeled full
binding, the basic patch on caspase-1 would also be pre- length ICEBERG. Levels of RNA were normalized to actin. Human
adult cDNA panels (Clontech) were amplified using primers specificdicted to bind an acidic patch on ICEBERG. However,
for ICEBERG, RIP2, or caspase-1. cDNA levels were normalized topreliminary mutagenesis experiments with ICEBERG sug-
human glyceraldehyde 3-phosphate dehydrogenase.gest a more complicated model (unpublished data).
Specifics of the interactions await detailed mutagenesis
Retroviral Constructs, Transduction, and ELISAand structural analyses of the ICEBERG/caspase-1 pro-
ICEBERG was cloned into the MSCV hygromycin-selectable retrovi-domain and the RIP2 CARD/caspase-1 prodomain com-
ral vector (Clontech) and recombinant virus obtained and titered
plexes. following transfections of a 293 Phoenix packaging cell line (Kinsella
and Nolan, 1996). Individual clones were assessed by immunoblot-
Experimental Procedures ting for expression of ICEBERG. Control THP.1 cells or those ex-
pressing ICEBERG were stimulated with the indicated amount of
Plasmids, Transient Transfection Assays, LPS and release of mature IL-1b determined using the Quantikine
Immunoprecipitation, and Western Blotting ELISA kit (R&D Systems) according to the manufacturer’s directions.
cDNAs encoding gD-tagged caspase-1, HA-tagged ICEBERG, and At least two separate clones expressing ICEBERG were tested with
Dprocaspase-1-FLAG (residues 103–404) were cloned into the mam- similar results. Isolated primary monocytes were treated with 100
malian expression vector pCDNA3. Expression constructs for FLAG- ng/mL of LPS, which was removed after 1 hr by extensive washing.
tagged wild-type and mutant caspase-1, -7, and -9 and for myc- The release of mature IL-1b was measured in the supernatant during
his-tagged RIP2 have been described elsewhere (Duan et al., 1996a, the indicated time periods as above.
1996b; McCarthy et al., 1998; Thome et al., 1998).
For transient transfections, 293T cells were transfected using
Protein Purification and Pure Protein Binding AssaysGenePorter (Gene Therapy Systems) according to the manufactur-
cDNAs encoding ICEBERG and the prodomain of caspase-1 (resi-er’s instructions. Cell lysis, immunoprecipitation analysis, and im-
dues 1–92) were cloned into pET21a (Novagen) modified to containmunoblotting were performed as described previously (McCarthy
argU (Garcia et al., 1986). The proteins were expressed fromet al., 1998) except for the addition of 3 mM DTT in the lysis buffer
BL21(DE3) cells (Stratagene) and grown in a 2.5 L fermentationand the use of a light chain specific antibody (HRP-conjugated goat
vessel (New Brunswick) in M9 minimal medium. For isotopic label-anti-mouse F(ab)92 – Jackson Labs) as the secondary reagent in
ing, the M9 medium contained 15N-NH4Cl (2 g/L) and/or 13C-glucoseWestern blotting. Immunoprecipitation for endogenous caspase-1/
(2.5 g/L) (Martek). Cells were homogenized and lysed in the presenceRIP2 interaction was performed using 5 3 108 THP.1 cells grown in
of 50 mM Tris (pH 8.0), 10mM DTT, 1mM EDTA, and protease inhibi-spinner flasks.
tors. The cell pellet was resuspended in phosphate buffered salineMonoclonal antibodies to caspase-1 prodomain, RIP2, and
(PBS) and 50 mM MgCl2 with 0.1 mg DNAase per 100 ml lysate.ICEBERG were made at Genentech using standard methods.
The mixture was stirred for 1 hr at room temperature and again
centrifuged. The resulting pellet was resuspended in 7 M Gu-HCl,
Metabolic Labeling
50 mM NaH2PO4 (pH 5.0), 5 mM DTT, and 5 mM EDTA and loadedFor ICEBERG expression and binding, 1 3 108 THP.1 cells or 2.5 3
onto a Sephacryl S-100 (Pharmacia) sizing column. For ICEBERG,
106 primary monocytes were exposed to 100 ng/mL of LPS (List
pooled protein fractions were diluted to 2 M Gu-HCl and refolded
Biological Laboratories) for the indicated time and labeled with 500
by dialysis with 50 mM NaH2PO4 (pH 5.0), 0.1 M NaCl, and 5mMmCi/mL of 35S-cysteine and methionine (Translabel from ICN). For
DTT at a protein concentration of 0.18 mg/mL. The protein was
caspase-1 and RIP2 binding, the same number of cells were labeled
dialyzed against 0.1% acetic acid and concentrated by lyophiliza-
as above for 30 min. Dialyzed fetal bovine serum tested for endotoxin
tion. The yield of purified protein was z175 mg/L of cell culture.
was used (HyClone). Cell lysis and reimmunoprecipitation analysis
For caspase-1 prodomain, the S-100 fractions were pooled and
were performed as described previously (O’ Rourke et al., 1992).
further purified on a C4 reverse phase HPLC column using a water/
acetonitrile gradient in the presence of 0.1% trifluoroacetic acid.
ICEBERG Stable Cell Lines and Activation Assays Caspase-1 prodomain fractions were next lyophilized and resus-
ICEBERG was cloned into the pCEP vector (Invitrogen) and stable pended in the 7 M Gu-HCl solution as above. The protein was then
clones made in 293T cells using standard molecular biology tech- diluted to 2 M Gu-HCl at a protein concentration of 0.1 mg/mL with
niques. For in vivo activation studies, cells were transfected and 50 mM NaH2PO4 (pH 5.0), 0.1 M NaCl, 5 mM DTT, and 5 mM EDTA
lysed in activation buffer as descibed previously (Stennicke and for refolding. Gu-HCl was removed by dialysis against the phosphate
Salvesen, 1997). For in vitro activation studies, in vitro translated buffer. The protein solution was subsequently dialyzed into 0.1%
caspase-1 was incubated in the presence of RIP2 with or without acetic acid, and concentrated by lyophilization. The yield of purified
ICEBERG in a total volume of 40 ml of activation buffer overnight at protein was z100 mg/L of cell culture. Electrospray mass spectrom-
378C. etry was used to verify the identity of the proteins; both purified
Cytosolic extracts for determining caspase-1 activity were pre- ICEBERG and the prodomain caspase-1 were found to lack the
pared as described previously (Yamin et al., 1996). Caspase-1 activ- N-terminal methionine residues.
ity was measured in undialyzed lysate by the cleavage of the fluores- ICEBERG was biotinylated with Sulfo-NHS-Biotin (Pierce). Bind-
cent peptide substrate Ac-WEHD-AMC as described previously ing assays were performed by incubating 4 mg of biotinylated
(Thornberry et al., 1997). ICEBERG with the caspase-1 prodomain at 48C overnight in PBS.
The volume was then brought up to 1 ml with 0.1% NP-40 lysis
buffer followed by addition of monoclonal antibody to caspase-1Cell Lines, RNA Isolation, and RT-PCR
THP.1 acute monocytic cells (ATCC) and human umbilical vein endo- prodomain or 10 ml streptavidin beads (Sigma). Immune complexes
were precipitated by the addition of Protein G beads (for cas-thelial cells (Clonetics) were cultured according to supplier’s instruc-
tions. Primary monocytes were isolated from whole blood using pase-1) or by streptavidin beads (for ICEBERG).
The CARD-containing segment of RIP2 (residues 454–540) wasLymphocyte Separation Medium (ICN). RNA was isolated from cells
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cloned into the pGEX6P vector, expressed, and immobilized onto Chou, J.J., Matsuo, H., Duan, H., and Wagner, G. (1998). Solution
structure of the RAIDD CARD and model for CARD/CARD interactionglutathione Sepharose beads. An excess of RIP2-glutathione Seph-
arose was incubated overnight with 4 mg of caspase-1 followed by in caspase-2 and caspase-9 recruitment. Cell 94, 171–180.
addition of 4 mg of ICEBERG as a competitor. For the in vitro activa- Day, C.L., Dupont, C., Lackmann, M., Vaux, D.L., and Hinds, M.G.
tion studies, caspase-1 was translated in the presence of 35S-Methi- (1999). Solution structure and mutagenesis of the caspase recruit-
onine (Amersham) using the TNT T7 Quick coupled transcription/ ment domain (CARD) from Apaf-1. Cell Death Differ. 6, 1125–1132.
translation system (Promega). Five microliters of labeled caspase-1
Dinarello, C.A. (1997). Proinflammatory and anti-inflammatory cyto-was incubated with RIP2-glutathione Sepharose with or without 10
kines as mediators in the pathogenesis of septic shock. Chest 112,mg of ICEBERG.
321S–329S.
Duan, H., Chinnaiyan, A.M., Hudson, P.L., Wing, J.P., He, W.W., andSolution Structure
Dixit, V.M. (1996a). ICE-LAP3, a novel mammalian homologue of theNMR spectra were acquired at 308C on a Bruker DRX-500 spectrom-
Caenorhabditis elegans cell death protein Ced-3 is activated duringeter equipped with a 5 mm inverse 1H/15N/13C-triple-resonance probe
Fas- and tumor necrosis factor-induced apoptosis. J. Biol. Chem.with three-axis gradient coils. Samples for NMR spectroscopy con-
271, 1621–1625.tained z2 mM ICEBERG, 50 mM sodium acetate-d3 (pH 3.8), 10–20
mM DTT-d10, and 1.0 mM NaN3. 1H and 15N resonance assignments Duan, H., Orth, K., Chinnaiyan, A., Poirier, G., Froelich, C.J., He,
were obtained using conventional NOESY-based methods (Wu¨th- W.-W., and Dixit, V.M. (1996b). ICE-LAP6, a novel member of the
rich, 1986). The following spectra were recorded using a 15N-labeled ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease
protein sample in 90% H2O/10% D2O: 2D 2QF-COSY, 2D 1H-15N Granzyme B. J. Biol. Chem. 271, 16720–16724.
HSQC, 3D TOCSY-HSQC (mixing times, 33 and 98 ms), 3D HNHA, 3D
Eberstadt, M., Huang, B., Chen, Z., Meadows, R.P., Ng, S.C., Zheng,HNHB, 3D 15N-NOESY-HSQC (mixing time, 100 ms), 3D 15N-HMQC-
L., Lenardo, M.J., and Fesik, S.W. (1998). NMR structure and muta-NOESY-HMQC (mixing time, 100 ms), and 3D 15N-ROESY-HSQC
genesis of the FADD (Mort1) death-effector domain. Nature 392,(mixing time, 40 ms) (Cavanagh et al., 1995). 13C resonance assign-
941–945.ments were completed using a uniformly 15N/13C-labeled protein
Fairbrother, W.J., Reilly, D., Colby, T.J., Hesselgesser, J., and Horuk,sample in 90% H2O/10% D2O and the following experiments: 2D
R. (1994). The solution structure of melanoma growth stimulating1H-13C HSQC, 3D CBCA(CO)NH, 3D HCCH-TOCSY, and 3D 13C-
activity. J. Mol. Biol. 242, 252–270NOESY-HSQC (mixing time 100 ms) (Cavanagh et al., 1995). Stereo-
specific assignment of methyl groups of Val and Leu residues were Fairbrother, W.J., Champe, M.A., Christinger, H.W., Keyt, B.A., and
obtained using a 15% 13C-labeled sample (Neri et al., 1989). Distance Starovasnik, M.A. (1998). Solution structure of the heparin-binding
and dihedral angle restraints were generated as described pre- domain of vascular endothelial growth factor. Structure 6, 637–648.
viously (Fairbrother et al., 1994, 1998). Structures of ICEBERG were
Garcia, G.M., Mar, P.K., Mullin, D.A., Walker, J.R., and Prather, N.E.calculated with a simulated annealing protocol using the program
(1986). The E. coli dnaY gene encodes an arginine transfer RNA.XPLOR 98.1 (Molecular Simulations, Inc.).
Cell 45, 453–459.
Ghayur, T., Banerjee, S., Hugunin, M., Butler, D., Herzog, L., Carter,Structural Alignments and Modeling
A., Quintal, L., Sekut, L., Talanian, R., Paskind, M., et al. (1997).Ca alignments with the CARDs of Apaf-1, caspase-9, and RAIDD
Caspase-1 processes IFN-gamma-inducing factor and regulateswere performed using the program ALIGN (Satow et al., 1986) and
LPS-induced IFN-gamma production. Nature 386, 619–623.coordinates from the PDB (1CY5, 3YGS, and 3CRD). Structures of
the prodomain of procaspase-1 and the CARD of RIP-2 were mod- Gu, Y., Wu, J., Faucheu, C., Lalanne, J.L., Diu, A., Livingston, D.J.,
eled using the Homology module of InsightII 98.0 (Molecular Simula- and Su, M.S. (1995). Interleukin-1 beta converting enzyme requires
tions, Inc.). oligomerization for activity of processed forms in vivo. EMBO J. 14,
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